News
Article
Author(s):
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.
(Image Credit: AdobeStock/Panumas)
UNITY Biotechnology, Inc. is set to host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024.
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Along with the data being presented during the scheduled event, the 24-week safety and efficacy data are expected in the first quarter of 2025. Further reporting is set to include 36-week data, which are expected in the second quarter of 2025.
According to a press release from the company, the agenda for the event is as follows:
Day: Tuesday, October 15, 2024
Time: 8:00 am until 9:30 am ET
Location: Park Terrace Hotel, New York, NY (with simultaneous webcast)
Registration and Webcast: https://lifescievents.com/event/unitybiotechnology/
Archived replays will be available for 90 days following the event on the company's website.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.